Temecula Valley Hospital is the first in California to bring applied artificial intelligence to stroke care

Dr. Hamed Farid, medical director of interventional neuro-radiology, views an image of the brain in the neuro-biplane room at Temecula Valley Hospital. Courtesy photo

TEMECULA – As one of the leaders in stroke care in Southern California, Temecula Valley Hospital continues its commitment to leveraging the most advanced innovations to improve access and optimize treatment for patients who are suffering an acute stroke. Viz.ai’s software allows Temecula Valley Hospital to further enhance the power of their stroke care team through quick detection and notification of suspected large vessel blockage in the brain. Through the use of artificial intelligence, stroke specialists can better synchronize timely care and determine the optimal patient treatment decision.

Stroke specialists with access to this new technology can potentially save critical minutes, even hours, in the triage, diagnosis and treatment of strokes. Combining groundbreaking applied artificial intelligence with seamless communication, Viz.ai’s image analysis facilitates fast and accurate triage of suspected blockages in stroke patients and better collaboration between clinicians at comprehensive and referral hospitals. Viz.ai synchronizes care across the whole care team so that the right patient gets to the right doctor at the right time.

“Viz.ai’s applied artificial intelligence solutions have been developed by top stroke clinicians and technical experts around the world and we are excited to be able to bring these transformational technologies to Temecula Valley Hospital and our community,” Darlene Wetton, CEO for Temecula Valley Hospital, said. “Viz.ai’s solutions will transform the way that we deliver stroke care to our community which we believe will result in improved outcomes for our patients.”

The new technology is transforming hospital workflow and synchronizing stroke care with a cloud-based artificial intelligence system that automatically analyzes CT scans for suspected blockages. It alerts neurovascular specialists and enables earlier imaging review and better collaboration between specialists.

“We are excited to partner with Temecula Valley Hospital, a first-class health system, with the foresight and commitment to providing cutting-edge artificial intelligence solutions to help transform health care and increase access to life-saving treatments for its patients and community,” Dr. Chris Mansi, CEO of Viz.ai, said.

Stroke is a leading cause of permanent disability, death and health care costs globally. According to the American Heart Association and American Stroke Association, stroke is the fifth leading cause of death in the U.S. and a leading cause of disability. When a stroke occurs, and the flow of oxygen-rich blood to a portion of the brain is blocked, approximately 2 million brain cells die every minute; in the case of stroke, “Time is Brain.”

Temecula Valley Hospital brings advanced technology, innovative programs, patient-centered and family sensitive care to area residents.  The hospital is nationally recognized as One of America’s Best Stroke Centers, the American Heart Association/American Stroke Association’s Get With The Guidelines-Stroke Gold Plus with Target Stroke Elite Plus Quality Achievement Award and Mission: Lifeline Bronze Receiving Achievement Award. For more information, visit www.temeculavalleyhospital.com.

Viz.ai is the leader in applied artificial intelligence in health care. Viz.ai’s mission is to fundamentally improve how health care is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.  In February 2018, the U.S. Food and Drug Administration granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage, and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering health care providers an important tool for automated cerebral perfusion image analysis.  Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.

Submitted by Temecula Valley Hospital.